Microbix granted patent on its Vaccine Technology
"This is a major milestone for Microbix as we move towards commercializing this important technology," said William J. Gastle, Chairman and CEO of the Company. "This is the first of a series of patents we expect will be granted in international markets where influenza vaccines are manufactured."
Last year, an independent laboratory confirmed that the Microbix' vaccine technology delivers a two-fold increase in the yield of human influenza virus from eggs. The independent evaluation was conducted by Dr. Todd Hatchette, the Director of Virology and Immunology at the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia. Dr. Hatchette is a specialist in the field of influenza virus.
Most read news
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.